Cue Health reels in $45M in series B financing for its diagnostic products

financial news
Investors in the financing round included Johnson & Johnson Innovation. (Pixabay)

Cue Health reeled in more than $45 million in series B financing the company said will be used to complete development and fund U.S. clinical studies of its first set of diagnostics products.

The San Diego-based company said investors in the financing round included Johnson & Johnson Innovation, Section 32, Dentsu Ventures, Synergy Ventures, Principles of Tarsadia Investments, Pritzker Group Venture Capital, Babel Ventures and Troy Capital. Returning investors included Sherpa Capital, Cove Investments and Rohan Oza.

Cue is currently developing a diagnostics platform that can be connected to remote devices like smartphones for use in home by both healthcare professionals and patients for faster and more convenient access to health information.

Featured Whitepaper

Accelerate Clinical Operations Across Sponsors, CROs, and Partners

The most advanced life sciences organizations know that digital innovation and multi-platform integrations are essential for enabling product development. New platforms are providing the life sciences industry with an opportunity to improve the efficiency of clinical trials and reduce costs while remaining compliant and reducing risk.

“The Cue team has done a great job in advancing our multidisciplinary product development and processes, and we are thrilled to have our new partners’ support as we continue on our journey,” Ayub Khattak, Cue Health’s chief executive, said in a statement.

Earlier this month, Cue received its ISO 13485 certification from the British Standards Institute. The certification is an internationally recognized standard for the development and manufacturing of diagnostic products for medical use. The FDA recently said it plans to adopt ISO 13485 as part of its efforts to be in line with international standards for the regulation of medical devices.

Read more on

Suggested Articles

According to a large clinical study, multifocal contact lenses were able to slow down and control the worsening of nearsightedness in children.

RapidAI has secured an FDA clearance for its artificial intelligence algorithms that quickly parse brain CT scans and spot suspected strokes.

The kits can connect 20 standard hospital beds to a central patient monitoring station and be up and running in an average of five hours.